Don't see anything?
So we are looking at a 12% dilution but won't know price until?
With this recent stock offering what does this equal as all stated in ASX not NASDAQ
Conclusion 5 → NurOwn's advantage vs. competitors looks to be its mode of administration and benign safety profile.
Brainstorm Cell Therapeutics is currently enrolling patients in a Phase 2 study (NCT02017912), with one site at the Mayo Clinic, the U.S. No. 1 ranked hospital for Neurology & Neurosurgery. A second site in this trial (there are three sites total), the Massachusetts General Hospital, is ranked No. 4 on that list. Earlier in the month, Emory University Neurologist and CNN Chief Medical Correspondent, Dr. Sanhay Gupta, wrote a brief article noting that there finally may be "Some Hope For People With ALS." We discussed this in an article posted on Seeking-Alpha last week.
We remain fans of Brainstorm Cell Therapeutics. We believe this is a stock investor should own at this level given a favorable risk / reward profile and tremendous upside for NurOwn in ALS, as well as other indications such as Autism and Multiple Sclerosis. As outlined in our Zacks report, we think the stock is worth $10 per share, which is a double from today's price.
Does not make any sense.
They have been talking about since the last run up.
Anyone know why the run up? No news. Anything pending?
Seems like someone with deep pockets could run this better; get through the ups and downs of this new technology.
600% with in a 12 month period and will dilute again by 300% within the next two years.
Come one GENE where are your buyers?
That is not a lot of shares.
Any possibility of going up?
Dropping like a rock. Who would trust this company after this.
because it is so expensive and invasive and expensive and the tech thought her lump was scar tissue. So now she is dying. A simple blood test would have detected her cancer and she could have been treated earlier. Please don't play with a company whose product is so desperately needed,